MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31.

Income Overview

Net Income
-$2,496,540
EPS
-$1.04
Unit: Dollar

Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
General and administrative expenses
1,742,315 2,302,141.5* 2,044,937 2,656,392
Research and development expenses
771,508 1,451,223.5* 688,465 1,077,498
Depreciation expense
555 5,671* 401 401
Total operating expenses
2,514,378 3,759,036 2,733,803 3,734,291
Loss from operations
-2,514,378 -3,759,036* -2,733,803 -3,734,291
Interest and dividend income
17,838 51,162 48,098 67,004
Total other income
17,838 51,162* 48,098 67,004
Net loss and comprehensive loss
-2,496,540 -3,707,874 -2,685,705 -3,667,287
Basic EPS
-1.04 -1.877 -1.31 -1.87
Diluted EPS
-1.04 -1.877 -1.31 -1.87
Basic Average Shares
2,407,665 1,975,596 2,044,033 1,961,642
Diluted Average Shares
2,407,665 1,975,596 2,044,033 1,961,642
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Interest and dividendincome$17,838 Net loss andcomprehensive loss-$2,496,540 Total other income$17,838 Loss from operations-$2,514,378 Total operatingexpenses$2,514,378 General andadministrative expenses$1,742,315 Research and developmentexpenses$771,508 Depreciation expense$555

Cadrenal Therapeutics, Inc. (CVKD)

Cadrenal Therapeutics, Inc. (CVKD)